Survivors of childhood Hodgkin's lymphoma at higher risk of future health problemsJune 02, 2008WINSTON-SALEM, N.C. - Adults who survived childhood Hodgkin's Lymphoma should be especially vigilant about cancer and cardiovascular screenings, according to researchers from Wake Forest University Baptist Medical Center and colleagues. Reporting at the annual meeting of the American Society of Clinical Oncology in Chicago today, Sharon Castellino, M.D., a pediatric oncologist, said a 26-center study of 1,927 Hodgkin's survivors found that treatments for the disease are associated with increased risk of dying from a second cancer or cardiovascular disease. "The bottom-line message is that a portion of those who survive Hodgkin's Lymphoma continue to have significant health needs beyond their five-year 'cure' mark," said Castellino, an assistant professor of pediatrics at Brenner Children's Hospital, part of Wake Forest Baptist. "Survivors and their doctors need to be aware of continued risks in adulthood from treatment received more than 20 years ago."
Hodgkin's Lymphoma is a growth of malignant cells in the lymph system, which is part of the immune system. The disease is one of the more curable cancers and "was one of the first successes in the 1970s," said Castellino. Currently, Hodgkin's Lymphoma has a 5-year survival rate of 90 percent. The disease most commonly occurs in the chest and its treatment involves radiation therapy of the neck and upper chest and/or chemotherapy. The goal of the study was to look at factors that may increase the risk of premature death. It involved 1,927 adults who were diagnosed between 1970 and 1986 at a median age of 14 years. They were followed for a median of 23 years through the Childhood Cancer Survivor Study (CCSS). There have been 320 deaths in the group with 30 percent due to recurrence, 26 percent to a second cancer and 19 percent to a cardiovascular event such as a heart attack or stroke. Among males, increased risk of premature death was associated with higher doses of chemotherapy regimens that included anthracycline drugs. In female five-year survivors, all doses of radiation therapy were associated with a higher risk of premature death. The development of second malignancies impacted survival in both sexes. In addition, a cardiovascular condition conferred a significant risk of death in male survivors. "It hadn't been clarified until this study that there was a different pattern of risks in men and women," said Castellino. "Other than a recurrence of the original cancer, the leading cause of death in women is breast cancer and for men it is cardiovascular events." Castellino said the findings about cardiovascular disease are especially disturbing because about 30 percent of study participants had smoked at some time. She said the findings could lead to prevention recommendations, such as earlier health screenings. "Currently, women who received treatment for the disease are advised to have mammograms as early as 25-years-old," she said. "But, currently there are no specific guidelines for heart disease prevention over those for the general population." Since the 1980s, radiation therapy doses have been lowered in children with the goal of successfully treating the disease without causing undue side effects from the treatment. However, Castellino said that even though radiation doses are lower and techniques are refined, the heart and other critical structures are often exposed to radiation. Castellino is continuing the research by working to learn more about what changes occur as a result of radiation and identifying ways to intervene - possibly with drugs - before the damage is done. Wake Forest University Baptist Medical Center | |||||||||||||||||||||
|
Related Lymphoma News Articles Researchers discover how rheumatoid arthritis causes bone loss Researchers have discovered key details of how rheumatoid arthritis (RA) destroys bone, according to a study published in the Aug. 22 edition of the Journal of Biological Chemistry. Duke chemists synthesize promising anti-cancer product Duke University chemists have patented an efficient technique for synthesizing a marine algae extract in sufficient quantities to now test its ability to inhibit the growth of cancerous cells while leaving normal cells unaffected. Children's national co-leads nationwide study of landmark sickle cell treatment Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease. Rheb's role in cancer Two independent papers in the August 15th issue of G&D identify the Rheb GTPase as a novel oncogene and a promising new chemotherapeutic target. Researchers find cancer-inhibiting compound under the sea University of Florida College of Pharmacy researchers have discovered a marine compound off the coast of Key Largo that inhibits cancer cell growth in laboratory tests, a finding they hope will fuel the development of new drugs to better battle the disease. Targeted drug therapy found effective in patients with common form of immune-mediated kidney disease The drug rituximab causes considerable kidney injury healing in patients with membranous nephropathy, a common form of kidney disease, according to a study appearing in the November 2008 issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that this condition, previously destined to progress to kidney failure in 30-40 percent of cases, can actually be healed in some patients. Exposure to Agent Orange linked to prostate cancer in Vietnam veterans UC Davis Cancer Center physicians today released results of research showing that Vietnam War veterans exposed to Agent Orange have greatly increased risks of prostate cancer and even greater risks of getting the most aggressive form of the disease as compared to those who were not exposed. New Guidelines for Treating Rheumatoid Arthritis Proven combinations of medicines and the introduction of new anti-arthritis drugs have significantly improved the treatment of rheumatoid arthritis (RA), according to guidelines issued by the American College of Rheumatology and co-authored by physicians at the University of Alabama at Birmingham (UAB). Plants make vaccine for treating type of cancer in Stanford study Plants could act as safe, speedy factories for growing antibodies for personalized treatments against a common form of cancer, according to new findings from the Stanford University School of Medicine. The findings came in the first human tests of an injectable vaccine grown in genetically engineered plants. CSHL scientists correlate enzyme expression levels with chemotherapy drug response Why do cancer patients develop resistance to chemotherapy drugs, sometimes abruptly, after a period in which the drugs seem to be working well to reduce tumors or hold them in check? Although largely a mystery to scientists, the result when this occurs is all too familiar: patients relapse and in many cases die when their cancers become resistant. More Lymphoma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||